


Express Mail Label No.: EK55367954US

Date of Deposit: May 10, 2000

Attorney Docket No. 00960-569



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Charette *et al.*

ASSIGNEE: Creative BioMolecules, Inc.

SERIAL NUMBER: 09/509,648

EXAMINER: Not Yet Assigned

INT'L FILING DATE: October 26, 1998

ART UNIT: Not Yet Assigned

FOR: ENHANCEMENT OF MORPHOGEN ACTIVITY

May 10, 2000

Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

- ☒ Information Disclosure Statement (3 pgs.);
- ☒ Form PTO 1449 (1 pg., in duplicate);
- ☒ Copy of three references (B1-B3); and
- ☒ Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at 617-542-6000, Boston, Massachusetts. Although Applicants believe no fees are due in connection with this filing, the Commissioner is hereby authorized to charge any deficiencies to the undersigned's Deposit Account No. 50-0311, Ref. No. 00960-569.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Michel Morency, Limited Recognition
James Gregory Cullem, Reg. No. 43,569
Attorney(s) for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Express Mail Label No.: EK555667954US

Date of Deposit: May 10, 2000

10 Rec'd OCT/PTO

2000

Attorney Docket No. 00960-569

10 Rec'd PCT/PTO

10 MAY 2000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Charette *et al.*

ASSIGNEE: Creative BioMolecules, Inc.

SERIAL NUMBER: 09/509,648

EXAMINER: Not Yet Assigned

INT'L FILING DATE: October 26, 1998

ART UNIT: Not Yet Assigned

FOR: ENHANCEMENT OF MORPHOGEN ACTIVITY

May 10, 2000

Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

Foreign Patent Documents:

WO 97/07135	Creative BioMolecules, Inc.	February 27, 1997
WO 96/40771	Creative BioMolecules, Inc.	December 19, 1996
WO 97/05285	Creative BioMolecules, Inc.	February 13, 1997

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☒ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☐ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner

APPLICANTS: Charette et al.
U.S.S.N.: 09/509,648

consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 00960-569.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Michel Morency, Limited Recognition
James Gregory Cullen, Reg. No. 43,569
Attorney(s) for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: May 10, 2000

TRADOCs:1314469.1(S691011.DOC)